Lu Hongbo, a director at Arrowhead Pharmaceuticals, sold 2,970 shares of common stock on May 12, 2026, at $76.88 per share, totaling $228,333.
The sale was executed under a pre-arranged 10b5-1 trading plan. Following the transaction, Lu directly holds 52,012 shares.
Arrowhead's stock has since risen to $79.69, trading near its 52-week high of $82.26, reflecting a 434% return over the past year for the $11.2 billion biotech firm.
In recent news, Arrowhead reported better-than-expected Q2 fiscal 2026 results. EPS loss of $0.93 beat the $1.04 loss forecast. Revenue of $74 million exceeded the $71.5 million estimate.
